Clik here to view.
TearLab receives U.S. patent for tear film collection and analysis
TearLab (NASDAQ:TEAR; TSX:TLB) was granted a U.S. patent for systems and methods of collecting tear film and measuring tear film osmolarity, which gives the company broad and blocking intellectual...
View ArticleClik here to view.
FDA grants CLIA-waiver for TearLab osmolarity test
The FDA has advised TearLab (NASDAQ:TEAR; TSX:TLB) that based on a supervisory review of the company’s appeal, the agency has granted its petition for a waiver under the Clinical Laboratory Improvement...
View ArticleClik here to view.
Roth ups TearLab price target to $3
Roth Capital Partners has raised its price target on “buy-rated” TearLab (NASDAQ:TEAR; TSX:TLB) to $3 from $2.20, citing a decision by the FDA to grant the TearLab Osmolarity System a waiver under the...
View ArticleClik here to view.
TearLab warrants exercised by institutional investors
Certain institutional shareholders of TearLab (NASDAQ:TEAR; TSX:TLB) have exercised 1,373,700 warrants into an equivalent number of common shares for gross proceeds of about $2.6 million. The warrants...
View ArticleClik here to view.
TearLab sees adoption curve rising for osmolarity test
TearLab (NASDAQ:TEAR; TSX:TLB) is confident that the adoption curve of its groundbreaking TearLab Osmolarity System for the diagnosis of dry eye disease “will steepen significantly in 2012,” says CEO...
View ArticleClik here to view.
Analysts bullish on TearLab results
Covering analysts gave TearLab Corporation (NASDAQ:TEAR; TSX:TLB) high marks after the company reported fourth quarter results yesterday and provided optimistic commentary around its expected ramp in...
View ArticleClik here to view.
Feltl starts TearLab at strong buy
Feltl and Company has initiated coverage of TearLab (NASDAQ:TEAR; TSX TLB: ) with a “strong buy” rating and $7 price target. The stock closed Wednesday at $4.22. “We view TearLab as deserving of a...
View ArticleClik here to view.
TearLab names Raymond Kong as VP sales
TearLab (NASDAQ:TEAR; TSX:TLB) has appointed Raymond Kong to its senior management team as VP of Sales. He succeeds Duane Morrison, who will shift his focus to major accounts and doctor networks in the...
View Article
